

# Haemoglobinopathies Market to Reach \$8.99 billion with 10.0% CAGR Forecast to 2022

*Haemoglobinopathies Market to Grow at a 10.0% CAGR Forecast to 2022*

PUNE, INDIA, October 7, 2016

/EINPresswire.com/ -- According to researcher, the Global Hemoglobinopathie market is accounted for \$4.6 billion in 2015 and is expected to reach \$8.99 billion by 2022 growing at a CAGR of 10.0% from 2015 to 2022.

Increasing incidences of hemoglobin disorders with strong product portfolio for sickle cell anemia such as HQK-1001 and Luspatercept, government's awareness programs and advanced diagnostics and therapeutics will fuel the market growth. Research & development and growth across developed and developing economies will provide opportunity for the market growth. Instrumentation cost and expertise required for LC MS/MS, molecular identification of the alpha and beta chain mutations are some of the factors that impede the market growth.

Complete report details @

<https://www.wiseguyreports.com/reports/674249-haemoglobinopathies-global-market-outlook-2016-2022> □



Hydroxyurea was one of the dominating segments followed by Thalassemia and is estimated to grow at lucrative growth rate. Blood tests and pre-implant genetic testing is anticipated to grow further during forecast period. The market for blood transfusion was the largest with revenues in therapeutic segment. North America dominated the overall market. Africa, Asia Pacific and the Mediterranean regions are projected to show profitable growth.

Some of the key players in global Hemoglobinopathie market are Gamida Cell, Alynlam Pharmaceuticals, Biogen Idec, Genetix Pharmaceuticals, Global Blood Therapeutics Inc., Pfizer Inc., Mast Therapeutics, Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, Celgene Corporation, HemaQuest Pharmaceuticals, Sangamo BioSciences Inc, Cancer Therapeutics CRC Pty Ltd, Datar Genetics Limited, Optinova Ab, Anthera Pharmaceuticals and AcceleronPharma.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/674249-haemoglobinopathies-global-market-outlook-2016-2022> □

Disorders Covered:

- Sickle Cell Disease
- Haemoglobin variants diseases
- o Haemoglobin C disease

## o Haemoglobin S-C disease

- Thalassemia

### Drugs Covered:

- NiCord
- ZFP Transcription Factors
- ALN-TMP
- Drug Targeting PRMT5
- Drug Targeting Protein Arginine Methyltransferase 5

### Diagnosis Covered:

- Genetic Testing
- Blood Testing
- Pre-implantation Genetic Diagnosis
- Prenatal Genetic Testing
- Haemoglobin Electrophoresis

### Therapies Covered:

- Iron Chelation Therapy
- Blood Transfusion
- Hydroxyurea
- Bone Marrow Transplant

### What our report offers:

- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/674249-haemoglobinopathies-global-market-outlook-2016-2022> □

### Key points in table of content

#### 1 Executive Summary

#### 2 Preface

##### 2.1 Abstract

##### 2.2 Stake Holders

##### 2.3 Research Scope

##### 2.4 Research Methodology

###### 2.4.1 Data Mining

###### 2.4.2 Data Analysis

###### 2.4.3 Data Validation

###### 2.4.4 Research Approach

##### 2.5 Research Sources

###### 2.5.1 Primary Research Sources

###### 2.5.2 Secondary Research Sources

###### 2.5.3 Assumptions

#### 3 Market Trend Analysis

##### 3.1 Introduction

##### 3.2 Drivers

##### 3.3 Restraints

3.4 Opportunities

3.5 Threats

3.7 Emerging markets

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Haemoglobinopathies Market, By Disorder

5.1 Introduction

5.2 Sickle Cell Disease

5.3 Haemoglobin variants diseases

5.3.1 Haemoglobin C disease

5.3.2 Haemoglobin S-C disease

5.4 Thalassemia

5.4.1 Alpha Thalassemia

5.4.2 Beta Thalassemia

6 Global Haemoglobinopathies Market, By Drug

6.1 Introduction

6.2 NiCord

6.3 ZFP Transcription Factors

6.4 ALN-TMP

6.5 Drug Targeting PRMT5

6.6 Drug Targeting Protein Arginine Methyltransferase 5

7 Global Haemoglobinopathies Market, By Diagnosis

7.1 Introduction

7.2 Genetic Testing

7.3 Blood Testing

7.4 Pre-implantation Genetic Diagnosis

7.5 Prenatal Genetic Testing

7.6 Haemoglobin Electrophoresis

8 Global Haemoglobinopathies Market, By Therapy

8.1 Introduction

8.2 Iron Chelation Therapy

8.3 Blood Transfusion

8.4 Hydroxyurea

8.5 Bone Marrow Transplant

9 Global Haemoglobinopathies Market, By Geography

9.1 North America

9.1.1 US

9.1.2 Canada

9.1.3 Mexico

9.2 Europe

9.2.1 Germany

9.2.2 France

9.2.3 Italy

9.2.4 UK

9.2.5 Spain

9.2.9 Rest of Europe

- 9.3 Asia Pacific
  - 9.3.1 Japan
  - 9.3.2 China
  - 9.3.3 India
  - 9.3.4 Australia
  - 9.3.5 New Zealand
  - 9.3.9 Rest of Asia Pacific
- 9.4 Rest of the World
  - 9.4.1 Middle East
  - 9.4.2 Brazil
  - 9.4.3 Argentina
  - 9.4.4 South Africa
  - 9.4.5 Egypt

## 10 Key Developments

- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies

## 11 Company Profiling

- 11.1 Gamida Cell
- 11.2 Alnylam Pharmaceuticals
- 11.3 Biogen Idec
- 11.4 Genetix Pharmaceuticals
- 11.5 Global Blood Therapeutics Inc.
- 11.6 Pfizer Inc.
- 11.7 Mast Therapeutics
- 11.8 Emmaus Life Sciences, Inc.
- 11.9 Prolong Pharmaceuticals
- 11.10 Celgene Corporation
- 11.11 HemaQuest Pharmaceuticals
- 11.12 Sangamo BioSciences Inc
- 11.13 Cancer Therapeutics CRC Pty Ltd
- 11.14 Datar Genetics Limited
- 11.15 Optinova Ab
- 11.16 Anthera Pharmaceuticals
- 11.17 AcceleronPharma

Buy this report @ [https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=674249](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=674249)

Norah Trent  
wiseguyreports  
+1 646 845 9349 / +44 208 133 9349  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.